Sin categoría – Página 18 – SEIOMM, Sociedad Española de Investigación Ósea

Fracture risk in type 2 diabetic patients: A clinical prediction tool based on a large population-based cohort

PLoS One. 2018 Sep 7;13(9):e0203533. doi: 10.1371/journal.pone.0203533. eCollection 2018. Martínez-Laguna D, Tebé C, Nogués X, Kassim Javaid M, Cooper C, Moreno V,Diez-Perez A, Collins GS, Prieto-Alhambra D.. https://www.ncbi.nlm.nih.gov/pubmed/30192850

Hypovitaminosis D: comparison between patients with hip fracture and patients with vertebral fractures.

Osteoporos Int. 2018 Jun 23. doi: 10.1007/s00198-018-4582-x. DOI: 10.1007/s00198-018-4582-x -PMID: 29934647 Giordano S(1), Proietti A(2), Bisaccia T(2), Caso P(2), Martocchia A(2), Falaschi P(2), Tafaro L(2).

Bone mineral density response rates are greater in patients treated with abaloparatide compared with those treated with placebo or teriparatide: Results from the ACTIVE phase 3 trial.

Bone. 2018 Oct 22;120:137-140. doi: 10.1016/j.bone.2018.10.015 Miller PD(1), Hattersley G(2), Lau E(3), Fitzpatrick LA(4), Harris AG(5), Williams GC(4), Hu MY(4), Riis BJ(6), Russo L(7), Christiansen C(6). DOI: 10.1016/j.bone.2018.10.015 -PMID: 30359763

High-serum phosphate and parathyroid hormone distinctly regulate bone loss and vascular calcification in experimental chronic kidney disease.

Nephrol Dial Transplant. 2018 Sep 5. Carrillo-López N, Panizo S, Alonso-Montes C, Martínez-Arias L, Avello N, Sosa P, Dusso AS, Cannata-Andía JB, Naves-Díaz M.

Do sarcopenia and/or osteoporosis increase the risk of frailty? A 4-year observation of the second and third ROAD study surveys.

Osteoporos Int. 2018 Jun 21. doi: 10.1007/s00198-018-4596-4. DOI: 10.1007/s00198-018-4596-4 -PMID: 29931626 Yoshimura N(1), Muraki S(2), Oka H(3), Iidaka T(2), Kodama R(4), Horii C(4), Kawaguchi H(5), Nakamura K(6), Akune T(6), Tanaka S(4). https://www.ncbi.nlm.nih.gov/pubmed/29931626

Administration of teriparatide for four years cyclically compared to two years daily in treatment Naïve and alendronate treated women.

Bone. 2018 Oct 21;120:246-253. doi: 10.1016/j.bone.2018.10.020. Cosman F(1), Nieves JW(2), Roimisher C(3), Neubort S(3), McMahon DJ(3), Dempster DW(4), Lindsay R(5). DOI: 10.1016/j.bone.2018.10.020 -PMID: 30355512

High risk and probability of progression to osteoporosis at 10 years in HIV-infected individuals: the role of PIs.

J Antimicrob Chemother. 2018 Sep 1;73(9):2452-2459. Negredo E, Langohr K, Bonjoch A, Pérez-Alvárez N, Estany C, Puig J, Rosales J, Echeverría P, Clotet B, Gómez G.

Screening for Osteoporosis to Prevent Fractures: US Preventive Services Task Force Recommendation Statement.

JAMA. 2018 Jun 26;319(24):2521-2531. doi: 10.1001/jama.2018.7498. DOI: 10.1001/jama.2018.7498 -PMID: 29946735 [Indexed for MEDLINE] US Preventive Services Task Force, Curry SJ(1), Krist AH(2)(3), Owens DK(4)(5), Barry MJ(6), Caughey AB(7), Davidson KW(8), Doubeni CA(9), Epling JW Jr(10), … Leer más

Denosumab effects on bone density and turnover in postmenopausal women with low bone mass with or without previous treatment.

Bone. 2018 Oct 4;120:44-49. doi: 10.1016/j.bone.2018.10.001. Tsourdi E(1), Makras P(2), Rachner TD(1), Polyzos S(3), Rauner M(1), Mandanas S(4), Hofbauer LC(5), Anastasilakis AD(6). DOI: 10.1016/j.bone.2018.10.001 -PMID: 30292818

Linking of psoriasis with osteopenia and osteoporosis: A cross-sectional study.

Indian J Dermatol Venereol Leprol. 2018 Sep 17. Martinez-Lopez A, Blasco-Morente G, Giron-Prieto MS, Arrabal-Polo MA, Luque-Valenzuela M, Luna-Del Castillo JD, Tercedor-Sanchez J, Arias-Santiago S.